版本:
中国

BRIEF-Corvus Pharmaceuticals announces interim safety and efficacy results from its ongoing Phase 1/1B study of CPI-444

April 4 Corvus Pharmaceuticals Inc:

* Corvus Pharmaceuticals announces interim results from ongoing Phase 1/1B study demonstrating safety and clinical activity of lead checkpoint inhibitor CPI-444 in patients with advanced cancers

* Trial data showed that treatment with CPI-444 as a single agent and in combination with atezolizumab was well tolerated

* Says CPI-444 has been well tolerated to date

* Of 37 patients who showed evidence of disease control, 23 remain on treatment Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐